Original Source(s)
Related Content
FDA expands bladder cancer therapy approval
The expansion offers another treatment option for patients with high-grade tumors following BCG failure.
by Mouj Hijazi
October 14, 2026
-
3 min
FDA clears targeted cholangiocarcinoma therapy
In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.
September 24, 2026
-
2 min
Cryptococcal cellulitis may lead to amputation
A splinter injury progressed to finger necrosis in a patient with MDS, despite antibacterial treatment and no clinically apparent systemic dissemination.
October 26, 2026
-
4 min
